Search results
Results from the WOW.Com Content Network
CervicalCheck is the national cervical screening programme. [14] It was launched in September 2008 as the public name of the National Cancer Screening Service. [15] In May 2008, then chief executive officer Tony O'Brien dismissed claims that misdiagnoses would result from the use of US-based lab Quest Diagnostics.
Cervical cancer screening is a medical screening test designed to identify risk of cervical cancer. Cervical screening may involve looking for viral DNA, and/or to identify abnormal, potentially precancerous cells within the cervix as well as cells that have progressed to early stages of cervical cancer .
In 2011, Vicky Phelan, a mother of two children from Annacotty, County Limerick, underwent a smear test for cervical cancer. Although her test showed no abnormalities, she was diagnosed with cervical cancer in 2014. An internal CervicalCheck review found the original result to be incorrect, but Phelan was not informed of this fact until 2017.
The screening, which tests for the presence of human papillomavirus (HPV) - the virus that causes cervical cancer - is offered by the NHS to all women and people with a cervix aged between 25 and 64.
The Papanicolaou test (abbreviated as Pap test, also known as Pap smear (AE), [1] cervical smear (BE), cervical screening (BE), [2] or smear test (BE)) is a method of cervical screening used to detect potentially precancerous and cancerous processes in the cervix (opening of the uterus or womb) or, more rarely, anus (in both men and women). [3]
The procedure is considered a screening test for cervical cancer and is complementary to Pap smear. The technique was initially developed by Adolf Stafl, MD, of Medical College of Wisconsin in 1981. [1] Unlike colposcopy, cervicography does not have a current CPT/HCPCS code and typically is not covered by most medical insurance companies.
Figures suggest that cervical screening is saving 5,000 lives each year in the UK by preventing cervical cancer. [131] About 1,000 women per year die of cervical cancer in the UK. All of the Nordic countries have cervical cancer-screening programs in place. [132] The Pap test was integrated into clinical practice in the Nordic countries in the ...
If the cancer screening does not change the treatment outcome, the screening only prolongs the time the individual lived with the knowledge of their cancer diagnosis. This phenomenon is called lead-time bias. [14] A useful screening program reduces the number of years of potential life lost and disability-adjusted life years lost. However ...